Abramson Cancer Center Experts Weigh in on Latest Cancer Research at ASCO


June 23, 2010

Patient Power Interviews with Abramson Cancer Center Physicians at ASCO

Patient Power host and founder, Andrew Schorr attends one of the biggest 2010 annual medical conference, ASCO. While there Andrew is interviewing several leading Penn Medicine experts about the major breaking news in urology and cancer. You'll hear the latest advances in research and the results of collaborations of top doctors from around the world in prostate cancer, melanoma, breast cancer, pancreatic cancer, proton therapy, female urinary incontinence and interstitial cystitis, also called bladder pain syndrome (BPS). These videos are posted as news breast. Find our what the latest news means for you, the patient. View Videos

________________________________________________________________________________________

Experts from the Abramson Cancer Center provided commentary on the latest research regarding novel therapies and new study results being presented at the 2010 meeting of the American Society of Clinical Oncology (ASCO), in Chicago.

Lynn Schuchter, MD, chief of the division of Hematology/Oncology, professor of Medicine and head of the Melanoma Program at the Abramson Cancer Center, spoke about a new treatment for advanced melanoma, ipilimumab. "We have not had any therapy that has prolonged survival," said Dr. Schuchter.

Coverage
CNBC video and article
Associate Press (AP) article
USA Today article
Reuters article
Dow Jones article
Bloomberg article
AFP article

Dr. Schuchter also spoke with Reuters about another enticing melanoma drug delivery system, which helped melanoma patients whose cancer had spread to their liver more than three times as long as patients treated with the best available care. "This clearly shows that you can deliver a much higher dose of chemotherapy and get a tumor response," said Dr. Schuchter... read more

While moderating an ASCO press conference discussing novel therapies, Dr. Schuchter also commented on a new treatment for medulloblastoma, targeting the "sonice hedgehog" pathway. "We don't have a lot of data on follow-up, but this is really an amazing proof-of-principle idea and this pathway looks to be relevant in many cancers," said Dr. Schuchter... read more (HealthDay News)
Medpage Today article

At the outset of the 2010 ASCO meeting, Dr. Schuchter spoke with AFP about exciting research looking to target genetic pathways and abnormalities that would be presented at the meeting... read more

Kathryn Schmitz, PhD, MPH
, an associate professor of Epidemiology and Biostatistics, presented guidelines at ASCO recommending that physicians prescribe exercise to their cancer patients... read more (Futurity.org)

Angela DeMichele, MD, MSCE, an associate professor of Hematology/Oncology and Epidemiology, spoke with HealthDay News about a new treatment for advanced breast cancer, derived from sea sponges, that extended the lives of women with metastatic breast cancer by about 2.5 months. "This is very promising because this is a drug that works when other treatments have failed," she said. "If it works well for patients who have already tried three or four other treatments, then it's exciting to think it may have a lot of activity in women who are newly metastatic or in an adjuvant setting. It's pretty rare to see a drug prolong overall survival in that setting." Read More

Naomi Haas, MD, the director of the Abramson Cancer Center's Prostate Cancer Program, spoke with the Associated Press Radio about a study which found that, for men with high-risk early prostate cancer, adding radiotherapy treatment improved overall survival. The story aired on national news broadcasts including Ring of Fire and Bloomberg's The First Word.


Penn Medicine Cancer Research and Experts at ASCO -- Media Toolkit and News Releases